Remazolam benzenesulfonate for sedation in painless gastroscopy

Analysis of effective dose and clinical effect of remazolam benzenesulfonate combined with alfentanil in painless endoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058938

Enrollment

Unknown

Registered

2022-04-20

Start date

2022-05-05

Completion date

Unknown

Last updated

2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

case series:Remazolam benzenesulfonate combined with alfentanil for sedation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years who have passed the evaluation of painless gastroscopy in the anesthesia clinic; 2. ASA grading ?-?; 3. The patient signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with bradycardia (HR<=50 times /min) and severe arrhythmia; 2. Patients complicated with unstable angina pectoris and myocardial infarction; 3. Uncontrolled hypertension, diabetes, hyperthyroidism; 4. Psychiatric diseases (such as schizophrenia, depression, etc.), epilepsy history and cognitive dysfunction; 5. Previous history of psychotropic drug and narcotic drug abuse; 6. Abnormal liver function, kidney function and coagulation function; 7. Pregnant or lactating patients; 8. Patients allergic to benzodiazepines.

Design outcomes

Primary

Measure	Time frame
Sedative effect score;Time of effect of sedation;Sedative efficiency;Awakening time;Under observation time;The occurrence of adverse reactions;Mean arterial pressure;Heart rate;Blood oxygen saturation;	—

Countries

China

Contacts

Public ContactWang Pingjuan

Anhui No.2 Provincial People's Hospital

1034541904@qq.com+86 13655606997

Outcome results